Specialty Pharmacy

Study demonstrates safety of oral immunotherapy for peanut allergy in large group of preschool-aged children.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses the evolving role of genomics in the treatment of prostate cancer.

Check back daily for our coverage of the Asembia Specialty Pharmacy Summit this week.

Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another cardiovascular event.

This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.

Samsung Bioepis’ etanercept-ykro (Eticovo) was approved to treat all of the indications of the reference product, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

The COAST-X clinical trial program is evaluating ixekizumab across various population subsets of patients with axial spondyloarthritis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

An analysis showed increasing rates of medical marijuana use for individuals diagnosed with cancer over a 10-year period.

Investigators used a CRISPR technique to expose weaknesses in the acute myeloid leukemia enzyme that many drugs target.

Announcement positions specialty pharmacy group for continued growth.

Top news of the day from across the health care landscape.

Risankizumab-rzaa (Skyrizi, AbbVie) is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

Top news of the day from across the health care landscape.

Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.

The potential for prescription drugs to cost more than $1 million for a treatment regimen creates a mixed bag of conundrums for the health care system.

Research investigates cytomegalovirus to understand the process of targeting HIV in order to eradicate it from the body.

Top news of the day from across the health care landscape.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, gives an overview of which clinical trials to watch in the chronic lymphocytic leukemia space.

This is the first indication for pembrolizumab (Keytruda, Merck) in advanced renal cell carcinoma.

In rare cases, patients with HIV can experience a paradoxical response to antiretroviral therapy known as extreme immune decline.

Top news of the day from across the health care landscape.

This approval marks the first generic naloxone nasal spray for use in a community setting by an individual without medical training.

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?

Sobetirome was shown to stimulate myelination in mice without the severe adverse effects commonly associated with thyroid hormone therapy for multiple sclerosis.